Candida *Aspergillus*

JMI Laboratories, North Liberty, Iowa, USA

- The US FDA recently approved rezafungin for the treatment of candidemia and invasive candidiasis in adults.
- In addition, rezafungin is in development to prevent invasive fungal disease caused by *Candida*, *Aspergillus*, and *Pneumocystis* spp.
- We evaluated the *in vitro* activity of rezafungin, caspofungin, micafungin, and anidulafungin against European fungal isolates causing invasive infection.

- A total of 981 isolates were collected (1/patient) in 2019–2021 from 19 medical centres located in Western Europe (W-EU; n=755; 15 centres; 9 countries) and Eastern Europe (E-EU; n=226; 4 centres; 4 countries; Figure 1).
- Isolates were identified by MALDI-TOF and/or sequencing and tested by CLSI broth microdilution.
- CLSI breakpoints (2022) were applied, including susceptible-only provisional breakpoints for rezafungin.
- Rezafungin-nonsusceptible isolates were submitted to *FKS* sequencing by whole genome sequencing.